21/66US=50 / Câncer
Ryan CJ. Development in the management of genitourinary malignancies: prostate cancer and renal cell carcinoma. In: Leong SPL, editor. From local invasion to metastatic cancer: involvement of distant sites through the lymphovascular system. New York: Humana Press, 2009. p. 533-44. ISBN 978-1-60327-086-1.

DOENCAS MALIGNAS DO APARELHO GENITURINARIO; CANCER DE PROSTATA; CARCINOMA DE CELULAS RENAIS; CASTRACAO-RESISTENTE O CANCER DE PROSTATA; ANDROGENIOS ADRENAIS; IMUNOTERAPIA; FASE II; ABIRATERONA; ATRASENTAN; BEVACIZUMAB; CALCITRIOL; QUIMIOTERAPIA; GVAX; IPILIMUMAB; IXABEPILONA; SATRAPLATIN; SIPULEUCEL-T; VEGF; SUNITINIB; SORAFENIB

22/66US=97 / Biol/Mol
Schneider V, Rischke HC, Drevs J. Tumor angiogenesis. In: Molls M, Vaupel P, Nieder C, Anscher MS. The impact of tumor biology on cancer treatment and multidisciplinary strategies. Baltimore: Springer, 2009. p. 39-50. (Medical Radiology Radiation Oncology) ISBN 978-3-540-74385-9.

ANGIOGENESE TUMORAL; VEGF; CRESCIMENTO TUMORAL; EGFR; SINALIZACAO INTRACELULAR; FISIOPATOLOGIA DA ANGIOGENESE; FISIOPATOLOGIA DA RADIACAO; SUBSTANCIAS ANTIANGIOGENICAS; QUIMIOTERAPIA; TERAPIA ANTIANGIOGENICA; RADIACAO

23/66US=49-F / Câncer
Jiang BH,Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. In: Woude GFV, Klein G. Advances in cancer research. Amsterdam: Elsevier, 2009. p. 19-65. ISBN 978-0-12-3744371.

PI3K/PTEN; SINALIZACAO NA ANGIOGENESE; SINALIZACAO TUMORIGENESE; ANGIOGENESE REGULADA POR VEGF; ABERRACOES GENETICAS DE PI3K, PTEN E AKT EM CANCER; PAPEIS DE PI3K E AKT NA REGULACAO DA ANGIOGENESE; CRESCIMENTO DO TUMOR; METASTASE DE TUMOR; ANGIOGENESE TUMORAL

24/66US=49-G / Câncer
Cuevas H, Boudreau N. Managing tumor angiogenesis: lessons from VEGF-resistant tumors and wounds. In: Woude GFV, Klein G. Advances in cancer research. Amsterdam: Elsevier, 2009. p. 25-42. ISBN 978-0-12-3747730.

GERENCIANDO ANGIOGENESE TUMORAL; LICOES DE VEGF-RESISTENTES TUMORES E FERIDAS; ANGIOGENESE; VEGF E ANGIOGENESE TUMORAL; VEGF E RECRUTAMENTO DE EPC NA ANGIOGENESE TUMORAL; LIMITACOES NO ALVO VEGF

25/66US=19 / Cab/Pescoço
Smith IM, Califano JA, Ha PK. Molecular gene alterations as early-detection markers. In: Koch WM. Head and neck cancer. Philadelphia: Saunders Elsevier, 2010. p. 1-18. (Early diagnosis and treatment of cancer series) ISBN 978-1-4160-5202-9.

ALTERACOES GENETICAS MOLECULARES; MARCADORES DE DETECCAO PRECOCE; MARCADORES MOLECULARES; ANALISE DE LINFONODOS; MODELO DE PROGRESSAO DO CANCER; MECANISMOS DE DETECCAO DO CANCER; ALTERACOES CITOGENETICAS; DETECCAO DE PCR; P53; MITOCONDRIA; METILACAO; DETECCAO DE VIRUS; PAPILOMAVIRUS HUMANO; HPV; VIRUS EPSTEIN-BARR; CARCINOMA NASOFARINGEO; NIVEIS SERICOS DE MARCADORES DE PROTEINAS; CD44; RECEPTORES DOS FATORES DE CRESCIMENTO EPITELIAIS; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); TECNICAS PROTEOMICAS

26/66US=28 / Biol/Mol
Hicklin DJ. Vascular endothelial growth factor family and its receptors. In: Teicher BA, Ellis LM. Antiangiogenic agents in cancer therapy. 2 ed. Houston: Humana Press, 2008. p. 3-26. ISBN 978-1-58829-870-6.

FACTORES DE CRESCIMENTO ENDOTELIAL VASCULAR; ANGIOGENESE; CANCER; FATOR DE CRESCIMENTO; LIGANTE; NEUROPILINA; RECEPTOR; VEGF

27/66US=28 / Biol/Mol
Lee S, Iruela-Arispe ML. The extracellular matrix and VEGF processing. In: Teicher BA, Ellis LM. Antiangiogenic agents in cancer therapy. 2 ed. Houston: Humana Press, 2008. p. 85-97. ISBN 978-1-58829-870-6.

MATRIZ EXTRA-CELULAR; PROCESSAMENTO DE VEGF; METALOPROTEINASES DA MATRIZ; FACTORES DE CRESCIMENTO; ANGIOGENESE; MICROAMBIENTE TUMORAL; CELULAS ENDOTELIAIS; NEOVASCULARIZACAO

28/66US=28 / Biol/Mol
Kabayashi H, DeBush LM, Lin PC. Angiopoietin/Tie2 signaling regulates tumor angiogenesis. In: Teicher BA, Ellis LM. Antiangiogenic agents in cancer therapy. 2 ed. Houston: Humana Press, 2008. p. 171-87. ISBN 978-1-58829-870-6.

ANGIOPOIETINA; AMARRAR; ANGIOGENESE TUMORAL; VEGF; CANCER; METASTASE

29/66US=28 / Biol/Mol
Nagy JA, Fu Y, Dvorak AM, Dvorak HF. Tumor blood vessels. In: Teicher BA, Ellis LM. Antiangiogenic agents in cancer therapy. 2 ed. Houston: Humana Press, 2008. p. 205-24. ISBN 978-1-58829-870-6.

VEGF-A; VASOS SANGUINEOS TUMORAIS; ANGIOGENESE; ARTERIOGENESE; VENOGENESIS

30/66US=28 / Biol/Mol
Maharaj ASR, D'Amore PA. VEGF in the adult. In: Teicher BA, Ellis LM. Antiangiogenic agents in cancer therapy. 2 ed. Houston: Humana Press, 2008. p. 245-59. ISBN 978-1-58829-870-6.

VEGF; ANGIOGENESE; PRE-ECLAMPSIA; TERAPIA ANTI-ANGIOGENICA; BEVACIZUMAB; CELULAS ENDOTELIAIS

31/66US=28 / Biol/Mol
Jain RK, Batchelor TT, Duda DG, Willett CG. Normalization of tumor vasculature and microenvironment. In: Teicher BA, Ellis LM. Antiangiogenic agents in cancer therapy. 2 ed. Houston: Humana Press, 2008. p. 261-76. ISBN 978-1-58829-870-6.

ANGIOGENESE; BIOMARCADOR; MRI; NORMALIZACAO; VEGF; TUMOR

32/66US=28 / Biol/Mol
Kerbel RS, Emmenegger U, Folkins C, Munoz R, Shaked Y. Metronomic low-dose antiangiogenic chemotherapy in mice and man. In: Teicher BA, Ellis LM. Antiangiogenic agents in cancer therapy. 2 ed. Houston: Humana Press, 2008. p. 277-96. ISBN 978-1-58829-870-6.

BAIXA DOSE DE QUIMIOTERAPIA; ANGIOGENESE TUMORAL; TERAPIA ANTIANGIOGENICA; ENSAIOS CLINICOS; CELULAS PROGENITORAS ENDOTELIAIS; VEGF; METASTASE; CANCER DE MAMA; CANCRO DO OVARIO; CICLOFOSFAMIDA

33/66US=28 / Biol/Mol
Han L, Lorincz AM, Sukumar S. Regulation of angiogenesis in cancer and its therapeutic implications. In: Teicher BA, Ellis LM. Antiangiogenic agents in cancer therapy. 2 ed. Houston: Humana Press, 2008. p. 331-49. ISBN 978-1-58829-870-6.

ANGIOGENESE; VEGF; SAGE; CANCER; ANTIANGIOGENICO

34/66US=28 / Biol/Mol
DuBois S, Demetri G. Angiogenesis and angiogenesis inhibition in sarcomas. In: Teicher BA, Ellis LM. Antiangiogenic agents in cancer therapy. 2 ed. Houston: Humana Press, 2008. p. 353-69. ISBN 978-1-58829-870-6.

SARCOMA; ANGIOGENESE; MESENQUIMAL; VEGF

35/66US=28 / Biol/Mol
Grothey A. Antiangiogenesis agents in colorectal cancer. In: Teicher BA, Ellis LM. Antiangiogenic agents in cancer therapy. 2 ed. Houston: Humana Press, 2008. p. 371-84. ISBN 978-1-58829-870-6.

CANCER COLORRETAL; QUIMIOTERAPIA; BEVACIZUMAB; VEGF; EGFR

36/66US=28 / Biol/Mol
Melchert M, List AF. Antiangiogenic agents in myeloid malignancies. In: Teicher BA, Ellis LM. Antiangiogenic agents in cancer therapy. 2 ed. Houston: Humana Press, 2008. p. 457-73. ISBN 978-1-58829-870-6.

SINDROMES MIELODISPLASICAS; LEUCEMIA MIELOIDE AGUDA; LEUCEMIA MIELOIDE CRONICA; DOENCAS REUMATICAS; ANGIOGENESE; NEOVASCULARIZCAO; VEGF

37/66US=433 / Tese/FAP
Costa AC. Impacto da expressão de fatores relacionados a hipóxia (HIF1A e VEGF) e metabolismo lipídico (LXRA, LXRB e PPARG) em tumores de cólon estádio clínico II e III). [Impact of expression of factors related to hypoxia (HIF1A and VEGF) and lipid metabolism (LXRA, LXRB and PPARG) in colon cancer clinical stage II and III]. São Paulo, 2012. 80 p. Dissertação(Mestrado)-Fundação Antônio Prudente.

Disponível em: http://accamargo.phlnet.com.br/MESTRADO/2012/AdrianoCarneiro/AdrianoCarneiro.pdf

Curriculum Lattes

NEOPLASIAS DO COLO; CANCER DE COLON; HIPOXIA; FATOR 1 INDUZIVEL POR HIPOXIA; FATORES DE CRESCIMENTO DO ENDOTELIO VASCULAR; LIPIDEOS. METABOLISMO

38/66US=67 / Biol/Mol
Goel A, Kozuch P. Molecularly targeted therapy in pancreatic cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 211-26. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER DE PANCREAS; TERAPIA ALVO MOLECULAR; BEVACIZUMABE; CETUXIMABE; ERLOTINIBE; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); TERAPIA ANTI-ANGIOGENICA

39/66US=67 / Biol/Mol
Ho C, Davies AM, Lara PN, Gautschi O, Mach PC, Gumerlock PH, Gandara DR. Untargeted use of targeted therapy: a dilemma in non-small cell lung cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 227-40. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER DE PULMAO DE CELULAS NAO-PEQUENAS; TERAPIA-ALVO; EGFR; VEGF; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL

40/66US=67 / Biol/Mol
Azad NS, Sarosy G, Kohn EC. Molecular targets in ovarian cancer and endometrial cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 291-308. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER DE OVARIO; CANCER ENDOMETRIAL; ALVOS MOLECULARES; TIROSINA-QUINASES; EGFR; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); ONCOGENE; GENES SUPRESSORES DE TUMOR

Primeira | Anterior | Próxima | Última